Pharmacological assessment of 3‐tert‐butylsydnone

W. H. Bulger, P. R. Wells, E. B. Roche

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The pharmacological effects of the mesoionic derivative, 3‐tert‐butylsydnone, were investigated. Administration to rats caused clonic convulsions. The CD50 of 3‐tert‐butylsydnone was 0.471 ± 0.033 mmole/kg. Trimethadione, but not phenytoin sodium or proadifen hydrochloride, protected the rat from the effects of 3‐tert‐butylsydnone. After administration of this compound, pentobarbital sodium sleeping time was reduced in the rat, but blood pressure and ECG were unchanged in the dog. Pretreatment of the mouse with 3‐tert‐butylsydnone did not influence the LD50 of epinephrine hydrochloride. The action of methacholine chloride in the rat was not blocked, and the pupil of the rabbit eye was unaffected. Tests for analgesic and oxytocic activity were negative. Chronic administration of a small dose to the rat for 70 days had no effect on blood glucose, blood urea nitrogen, hemoglobin, or microhematocrit values.

Original languageEnglish (US)
Pages (from-to)109-111
Number of pages3
JournalJournal of Pharmaceutical Sciences
Issue number1
StatePublished - Jan 1976
Externally publishedYes


  • 3‐tert‐Butylsydnone—pharmacological and toxicological evaluation
  • Pharmacology—screening of 3‐tert‐butylsydnone
  • Sydnones—pharmacological and toxicological evaluation of 3‐tert‐butylsydnone

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Pharmacological assessment of 3‐tert‐butylsydnone'. Together they form a unique fingerprint.

Cite this